Pfizer’s Upjohn changed in business name to Viatris

Korea Corporation, Sales and Staff size is considerable due to market characteristics

New pharmaceutical company with blockbusters, including Lipitor

Pfizer's Upjohn is expected to be reborn as a complete independent corporation, or one pharmaceutical company, next year.

 

According to the relevant industry, Pfizer and Mylan decided to change the name of the company to Viatris in 2020 after the merger of the patent expiry division.

 

This means complete company separation.

 

Currently, Pfizer’s Upjohn is still operating under Pfizer's name under Pfizer Pharmaceutical.

 

In fact, Pfizer Korea general manager, Oh Dong-wook is also in charge of the two subsidiaries.

 

As Mylan has not entered the Korean market yet, the Pfizer’s Upjohn’s business division will be operated under Pfizer's control for the time being, but in the end, independence will be achieved if all the matters are prepared with the name’s change in the next year.

 

In particular, due to the nature of the domestic market, the sales volume of expired patented drugs is not small, and Pfizer's Upjone has big items such as Lipitor (Atorvastatin calcium), Norvasc (Amlodipine besylate), and Celebrex (Cerecoxib).

 

So, Pharmaceutical company of a certain scale is expected to be established.

 

Compared to global corporations, the number of employees in Korean subsidiaries is also overwhelming.

 

CEO Dong-wook Oh reorganized the company's internal corporate structure into Pfizer Korea Pharmaceutical which specializes in innovative drugs based on the development of new drugs, and Pfizer Korea Upjohn with concentrating on off-patent brands and generic drugs.

 

He said, "We look forward to growth potential to be better realized in each area“ He said, "We will focus on improving the quality of life by providing timely treatments to more patients based on the various drug pipelines and medicines in each business division.

 

It is the stage to discuss which direction to take, and also, Employees' roles and responsibilities remain unchanged in this process.

 

”